|Bid||12.25 x 100|
|Ask||17.00 x 600|
|Day's Range||16.10 - 16.85|
|52 Week Range||7.75 - 32.20|
|PE Ratio (TTM)||-2.13|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||16.09|
NEW YORK, NY / ACCESSWIRE / June 21, 2017 / It may have been a down market on Tuesday but neither Agenus nor Impax were down yesterday. Both stocks soared with Impax closing with gains of about 8% and ...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Impax Laboratories, Inc. a score of 16. Our analysis is based on comparing Impax Laboratories, Inc. with the following peers – Mylan N.V., Lannett Company, Inc., Pfizer Inc., Shire PLC Sponsored ADR, Valeant Pharmaceuticals International Inc, Endo International Plc, Astrazeneca PLC Sponsored ADR and Teva Pharmaceutical Industries ... Read more (Read more...)
Adamis Pharmaceuticals, Impax Laboratories and Accorda Therapeutics were among the biotech stock movers in premarket trading on June 16.